Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

144 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-18

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Impact of the Comprehensive Geriatric Assessment on the Quality of Life of elderly onco-hematologic patients' candidates for complex antitumoral therapies: clinical and biological correlatives

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

NCT02164071

Myelodysplastic Syndromes Leukemia Myeloid Acute Multiple Myeloma +1 more

COMPLETED

Quality of Life in Caregivers of Hospitalized Older Patients With Cancer

NCT01866969

Hematopoietic/Lymphoid Cancer Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED NA

Cohort of Patients Over 70 Years of Age With Cancer and / or Hematological Malignancy

NCT03960593

Cancer and / or Hematological Malignancy

UNKNOWN

Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients

NCT02317757

Cancer

UNKNOWN

Predicting Chemo Toxicity Using Geriatric Forms

NCT07163169

Oncology Geriatric Oncology Physiology

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The screenings for the next 2 decades indicate an exponential increase in the incidence of neoplastic diseases in the elderly population. In order to successfully balance effectiveness and low toxicity of immunochemotherapy, a treatment personalisation based on an objective evaluation of fitness is therefore needed. The use of geriatric screening is a first step to rationalize decisions in this regard, the G8 tool has demonstrated the ability to identify patients and mostly to objectively separate elderly fragile patients from those who are fit. In that consideration, the individualization of the anticancer treatment based on a Comprehensive Geriatric Assessment (CGA) is desirable in elderly fragile patients with solid or haematological malignancy. Cancer mortality is constantly increasing after 65 years and the consequent increase in life expectancy favour the processes of cellular senescence. In this context G8 fragility assessment will take place in the screening test and by using the EORTC QLQ-C30C questionnaire to assess quality of life (QoL). The evaluation of senescent cells will be done by real-time PCR. Our aims are i) to evaluate the impact of the CGA on the QoL of elderly onco-haematological patients, candidates for complex therapies, that resulted as fragile at the G8 geriatric screening and ii) to evaluate the senescent cells in the peripheral blood of the patients enrolled in the study. The study is expected to contribute to precision medicine management of elderly patients and refine the therapeutic stratifications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Malignancies Solid Tumor Elderly Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Geriatric evaluation Group

Geriatric evaluation of the proportion of elderly patients in which the treatment is modified based on the complete geriatric assessment (CGA)

No interventions assigned to this group

Control Group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged ≥ 65 years
* Diagnosis of solid or hematologic cancer
* Patients who are candidates for a first line therapy for advanced disease to be treated with biological target drugs, or candidates for integrated radiotherapy
* Patient with G8 scores ≤ 14/17

Exclusion Criteria

* Patients aged less than 65 years
* Patients who have received or currently in treatment for solid or hematologic cancer
* Patient with G8 scores more than 14/17

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No